Pharmaceuticals, Biotechnology and Life Sciences
Oxford Drug Design is among the first three companies to be awarded a share of a £3 million Collaborative Discovery Programme (CDP) announced by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate.
RALEIGH, N.C.–(BUSINESS WIRE)–Arrevus Inc. (www.arrevus.com), a biotechnology company developing novel therapeutics for patients with unmet medical needs, today announced the…
Vertex got a deal with NHS England, to enable eligible patients with cystic fibrosis in England the access to Orkambi…
Vertex Pharmaceuticals received FDA’s approval for Trikafta (elexacaftor/tezacaftor/ivacaftor), for treating cystic fibrosis in patients older than 12, who have at…
-Boehringer Ingelheim is enrolling first patient to test nvestigational compound BI ENaC inhibitor delivered twice daily via the Respimat, a…
Proteostasis Therapeutics has started with the phase 2 study of cystic fibrosis treatment by dosing the first patient, after a successful Phase 1 test of PTI’s combinations.
-Opportunity to treat the underlying cause of CF earlier than ever before- -Safety data from Phase 3 ARRIVAL study support…
Vertex Pharmaceuticals wants to submit a New Drug Application in the USA, so it will soon give the final test…
Vertex Pharmaceuticals Incorporated can now offer Symdeko for treating the underlying cause of cystic fibrosis (CF) for more certain patients.…
The U.S. Food and Drug Administration (FDA) expanded the approved indication for Vertex Pharmaceuticals’ Kalydeco (ivacaftor) for the treatment of cystic fibrosis (CF).